Porovnat metody
Prohlédněte si vybrané metody vedle sebe; řádky, které se liší, jsou zvýrazněny.
| Nástroj Cochrane pro riziko zkreslení 2.0 pro randomizované kontrolované studie× | CONSORT Reporting Checklist× | |
|---|---|---|
| Obor | Metodologie výzkumu | Metodologie výzkumu |
| Rodina | Process / pipeline | Process / pipeline |
| Rok vzniku≠ | 2019 | 2010 (original 1996) |
| Tvůrce≠ | Jonathan Sterne, Julian Higgins (Cochrane Collaboration) | Schulz et al. (CONSORT Group) |
| Typ≠ | Clinician-rated / Research team assessment | Trial author reporting checklist |
| Původní zdroj≠ | Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. DOI ↗ | Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI ↗ |
| Další názvy | RoB 2.0, RoB 2 | CONSORT, CONSORT 2010 |
| Příbuzné | 4 | 4 |
| Shrnutí≠ | RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias. | The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research. |
| ScholarGateDatová sada ↗ |
|
|